Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 11 of 25 for:    gestodene

OCP Pretreatment in PCOS Patients Undergoing ICSI Using Antagonist Protocol

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03881904
Recruitment Status : Recruiting
First Posted : March 20, 2019
Last Update Posted : March 20, 2019
Sponsor:
Information provided by (Responsible Party):
Khaled Afifi, Ain Shams University

Brief Summary:

373 women with PCOS undergoing a trial of IVF/ICSI will receive OCP from day 2 of the preceding cycle for 21 days followed by GnRH antagonist COH.

Another 373 women with PCOS undergoing a trial of IVF/ICSI will start GnRH antagonist COH directly without OCP pretreatment.

Both groups will be followed up for effect on ongoing pregnancy rate.


Condition or disease Intervention/treatment Phase
Subfertility, Female Drug: 0.075mg gestodene/0.03mg ethinylestradiol Phase 1 Phase 2

Detailed Description:

The study will include 740 women with polycystic ovary syndrome undergoing IVF/ICSI cycle using flexible antagonist protocol.

Randomization:

Patients fulfilling the inclusion criteria will be randomized to two groups.

Study Group:

This group will include 373 women with PCOS undergoing a trial of IVF/ICSI. This group will receive OCP from day 2 of the preceding cycle for 21 days followed by GnRH antagonist COH.

Control Group:

This group will include 373 women with PCOS undergoing a trial of IVF/ICSI. This group will start GnRH antagonist COH directly without OCP pretreatment.

Random allocation sequence generation:

A computer generated list via MedCalc ® Software, version 13.2.2 will be used, assigning each participant number to either study groups.

Allocation Concealment:

Assignment will be done by sequentially numbered, otherwise identical, sealed envelopes (SNOSE), each containing a 2-inch by 2-inch paper with a written code designating the assigned group. These papers will be placed in a folded sheet of aluminum foil fitted inside the envelope. Effort will be taken to assure absence of any detectable differences in size or weight between intervention and control envelopes. Envelopes will be chosen to be opaque and lined inside with carbon paper. Envelopes will be opened sequentially only after writing the subject's tracking information on the envelope so that the carbon paper served as an audit trail.

IVF/ICSI cycle will be done using flexible anatgonist protocol in both groups.

Primary outcome will be ongoing pregnancy rate.

Secondary outcomes will be biochemical and clinical pregnancy rates.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 740 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Oral Contraceptive Pill Pretreatment in Polycystic Ovary Syndrome Patients Undergoing IVF/ICSI Using the Gonadotrophin Releasing Hormone Antagonist Protocol (A Randomized Controlled Trial)
Actual Study Start Date : June 1, 2017
Estimated Primary Completion Date : July 1, 2019
Estimated Study Completion Date : July 1, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: OCP Group
This group will include 373 women with PCOS undergoing a trial of IVF/ICSI. This group will receive 0.075mg gestodene/0.03mg ethinylestradiol (Gynera®, Bayer Schering Pharma AG, Germany) from day 2 of the preceding cycle for 21 days followed by GnRH antagonist COH.
Drug: 0.075mg gestodene/0.03mg ethinylestradiol
OCPs will be started from day 2 of the cycle preceding COH and continued for 21 days, then induction of ovulation using antagonist protocol will be started.
Other Name: Gynera®

No Intervention: Control Group
This group will include 373 women with PCOS undergoing a trial of IVF/ICSI. This group will start GnRH antagonist COH directly without OCP pretreatment.



Primary Outcome Measures :
  1. Ongoing pregnancy rate [ Time Frame: 20 gestational weeks ]
    Number of pregnancies completing ≥20 weeks gestational age expressed per 100 embryo transfer cycles


Secondary Outcome Measures :
  1. Chemical pregnancy rate [ Time Frame: 6 gestational weeks ]
    Number of biochemical pregnancies (evidenced by positive pregnancy test in serum or urine without ultrasound evidence of a gestational sac) expressed per 100 embryo transfer cycles

  2. Clinical pregnancy rate [ Time Frame: 6 gestational weeks ]
    Number of clinical pregnancies (evidenced by ultrasound visualization of a gestational sac and embryonic pole with heartbeat) expressed per 100 embryo transfer cycles

  3. Live birth rate [ Time Frame: 38 gestational weeks ]
    The number of deliveries (> 28 weeks GA) that resulted in a live born neonate, expressed per 100 embryo transfers



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 39 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age 18-39 years of age.
  2. BMI 18-29 Kg/m2
  3. Polycystic ovary syndrome, diagnosed - according to the revised 2003 consensus on diagnostic criteria of polycystic ovary syndrome by the Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group - by the presence of two of the following three diagnostic features:

    1. Oligo- or anovulation [defined as fewer than eight episodes of menstrual bleeding per year or menses that occur at intervals greater than 35 days].
    2. Clinical hyperandrogenism [defined by the presence of hirsutism (assessed by a modified Ferriman-Gallwey score ≥ 8), acne or androgenic alopecia] and/or biochemical signs of hyperandrogenism [defined by elevated free androgen index]
    3. Polycystic ovaries [defined as presence of 12 or more follicles in each ovary measuring 2 - 9 mm in diameter, and/or increased ovarian volume > 10 mL) in the early follicular phase (cycle days 3 - 5) in regularly menstruating women. Oligo-/amenorrhoeic women should be scanned either at random or between days 3 and 5 after a progestin-induced withdrawal bleeding. This definition does not apply to women taking oral contraceptive pills, since their use modifies ovarian morphology in normal women and putatively in women with PCO.

    After exclusion of other etiologies (congenital adrenal hyperplasia, androgen secreting tumors, Cushing's syndrome, hypothyroidism and hyperprolactinemia).

  4. Normal transvaginal ultrasonography apart from polycystic ovaries (see before).
  5. Normal office hysteroscopy.
  6. Normal hysterosalpingography.
  7. Absence of any structural pathological findings in laparoscopy apart from enlarged sclerotic polycystic ovaries.
  8. Normal hormonal profile (apart from hormonal abnormalities associated with PCOS), e.g. normal thyroid function tests
  9. Normal parameters of male semen analysis according to WHO criteria 2010.
  10. First trial IVF/ICSI.
  11. Written and signed informed consent by the patient to participate in the study.

Exclusion Criteria:

  1. Age more than 39 years.
  2. BMI more than 29 Kg/m2
  3. Abnormal ultrasonographic finding, e.g. endometrial polyps, fibroids or ovarian cysts.
  4. Abnormal hysteroscopic finding, e.g. endometrial polyps, endometrial hyperplasia or fibroid.
  5. Abnormal hysterosalpingographic finding, e.g. hydrosalpinx or peritoneal adhesions.
  6. Abnormal male or female karyotyping.
  7. Abnormal endocrinological profile during ovarian stimulation not attributed to PCOS, e.g. hypothyroidism, FSH > 12 mIU/mL on day 3.
  8. Previous trials of IVF/ICSI.
  9. Positive anticardiolipin antibodies or lupus anticoagulant.
  10. Positive thrombophilia screen.
  11. Abnormal semen analysis parameters according to WHO criteria 2010.
  12. Any hormonal treatment within the last 3 months.
  13. Any treatment for insulin resistance within the last 3 months, e.g. metformin or leptin.
  14. Any chronic medical disorder, e.g. hypertension, autoimmune disorders, … etc.
  15. Any category 4 medical condition that contraindicates the usage of OCP according to the WHO Medical eligibility criteria, 2015:

    • Smoking with age ≥ 35 years and cigarettes ≥ 15 /day.
    • Hypertension (systolic ≥ 160 mmHg or diastolic ≥ 90 mmHg).
    • Hypertension with vascular disease.
    • Previous history or acute DVT/PE.
    • Any known thrombogenic mutations.
    • Complicated valvular heart disease.
    • Systemic lupus erythematosus with positive or unkown antiphospholipid antibodies.
    • Migraine with aura.
    • Diabetes with nephropathy/neuropathy/retinopathy.
    • Diabetes > 20 years.
    • Acute hepatitis, severe cirrhosis or liver tumors.
  16. Mental condition rendering the patients unable to understand the nature, scope and possible consequences of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03881904


Contacts
Layout table for location contacts
Contact: Khaled Afifi, MSc 01009981222 DrKhaledAfifi@hotmail.com

Locations
Layout table for location information
Egypt
AinShams Maternity Hospital Recruiting
Cairo, Egypt, 002
Contact: Khaled Afifi, MSc    01009981222    DrKhaledAfifi@hotmail.com   
Sponsors and Collaborators
Ain Shams University
Investigators
Layout table for investigator information
Principal Investigator: Mostafa Fouad, MD Assistant Professor
Study Director: Ahmed Abbas, MD Lecturer

Layout table for additonal information
Responsible Party: Khaled Afifi, Assistant lecturer of O&G, Ain Shams University
ClinicalTrials.gov Identifier: NCT03881904     History of Changes
Other Study ID Numbers: OCP-AntagonistPCOS
First Posted: March 20, 2019    Key Record Dates
Last Update Posted: March 20, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Khaled Afifi, Ain Shams University:
PCOS
Anatgonist protocol
OCP pretreatment
Additional relevant MeSH terms:
Layout table for MeSH terms
Gestodene
Infertility
Infertility, Female
Genital Diseases, Male
Genital Diseases, Female
Ethinyl Estradiol
Estrogens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Contraceptives, Oral, Synthetic
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Progestins